Update on the management of polycystic ovary syndrome

Pharmacological Reports

Volumn 58, Issue 5, 2006, Pages 614-625

  Krysiak, Robert ^a   Okopień, Bogusław ^a   Gdula Dymek, Anna ^a   Herman, Zbigniew Stanisław ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Hormonal therapy; Insulin resistance; Insulin sensitizing agents; Polycystic ovary syndrome

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIANDROGEN; CLOMIFENE CITRATE; CYPROTERONE ACETATE; DEXAMETHASONE; ESTROGEN; FINASTERIDE; FLUTAMIDE; FOLLITROPIN; GESTAGEN; GLUCOCORTICOID; GONADORELIN; GONADORELIN DERIVATIVE; GONADOTROPIN DERIVATIVE; HUMAN MENOPAUSAL GONADOTROPIN; HYDROCORTISONE; INSULIN SENSITIZING AGENT; KETOCONAZOLE; LEVONORGESTREL; LONG ACTING DRUG; MEDROXYPROGESTERONE ACETATE; METFORMIN; NALTREXONE; ORAL CONTRACEPTIVE AGENT; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SPIRONOLACTONE; TROGLITAZONE; UNINDEXED DRUG;

ACNE; ADRENAL DISEASE; ALOPECIA; ANOVULATION; BODY WEIGHT DISORDER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIET THERAPY; DISEASE ASSOCIATION; DRUG DOSE REGIMEN; DRUG POTENTIATION; GASTROINTESTINAL SYMPTOM; HIRSUTISM; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; HYPERKALEMIA; HYPOPHYSIS DISEASE; HYPOTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LACTIC ACIDOSIS; LIFESTYLE; LIVER TOXICITY; MATERNAL AGE; MENSTRUAL IRREGULARITY; MORBIDITY; NONHUMAN; OVARY DISEASE; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; PERIPHERAL EDEMA; POLYURIA; PREGNANCY DIABETES MELLITUS; REVIEW; RISK FACTOR; TERATOGENICITY; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 33750996161     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Amin M, Abdel-Kareem O, Takekida S, Moriyama T, Abd el-Aal G, Maruo T: Up-date management of non responder to clomiphene citrate in polycystic ovary syndrome. Kobe J Med Sci, 2003, 49, 59-73.
2. Archer JS, Chang RJ: Hirsutism and acne in polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol, 2004, 18, 737-754.
3. Baillargeon JP: Use of insulin sensitizers in polycystic ovarian syndrome. Curr Opin Investig Drugs, 2005, 6, 1012-1022.
4. Baillargeon JP, Iuorno MJ, Jakubowicz D: Metformin therapy increases insulin-stimulated release of D-chiroinositol-containing inositolphosphoglycan mediator in women with polycystic ovary syndrome. J Clin Endocrinol Metab, 2004, 89, 242-249.
5. Baillargeon JP, Iuorno MJ, Nestler JE: Insulin sensitizers for polycystic ovary syndrome. Clin Obstet Gynecol, 2003, 46, 325-340.
6. Beck J, Boothroyd C, Proctor M, Farquhar C, Hughes E: Oral anti-oestrogens and medical adjuncts for subfertility associated with anovulation. Cochrane Database Syst Rev, 2005, 1, CD002249.
7. Ben-Haroush A, Yogev Y, Fisch B: Insulin resistance and metformin in polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol, 2004, 115, 125-133.
8. Bruni V, Dei M, Pontello V, Vangelisti P: The management of polycystic ovary syndrome. Ann N Y Acad Sci, 2003, 997, 307-321.
9. Cheang KI, Nestler JE: Should insulin-sensitizing drugs be used in the treatment of polycystic ovary syndrome? Reprod Biomed Online, 2004, 8, 440-447.
10. Christy NA, Franks AS, Cross LB: Spironolactone for hirsutism in polycystic ovary syndrome. Ann Pharmacother, 2005, 39, 1517-1521.
11. Coccia ME, Comparetto C, Bracco GL, Scarselli G: GnRH antagonists. Eur J Obstet Gynecol Reprod Biol, 2004, 115, Suppl 1, S44-S56.
12. Crosby PD, Rittmaster RS: Predictors of clinical response in hirsute women treated with spironolactone. Fertil Steril, 1991, 55, 1076-1081.
13. De Leo V, la Marca A, Petraglia F: Insulin-lowering agents in the management of polycystic ovary syndrome. Endocr Rev, 2003, 24, 633-667.
14. Dereli D, Dereli T, Bayraktar F, Ozgen AG, Yilmaz C: Endocrine and metabolic effects of rosiglitazonee in non-obese women with polycystic ovary disease. Endocrine J, 2005, 52, 299-308.
15. Diamanti-Kandarakis E, Baillargeon JP, Iuorno MJ, Jakubowicz DJ, Nestler JE: A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills. J Clin Endocrinol Metab, 2003, 88, 1927-1932.
16. Diamanti-Kandarakis E, Papailiou J, Palimeri S: Hyper-androgenemia: pathophysiology and its role in ovulatory dysfunction in PCOS. Pediatr Endocrinol Rev, 2006, 3, Suppl 1, 198-204.
17. Ehrmann DA, Rychlik D: Pharmacologic treatment of polycystic ovary syndrome. Semin Reprod Med, 2003, 21, 277-283.
18. Essah PA, Nestler JE: The metabolic syndrome in polycystic ovary syndrome. J Endocrinol Invest, 2006, 29, 270-280.
19. Farquhart C, Lilford RJ, Marjoribanks J, Vandekerckhove P: Laparoscopic "drilling" by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome. Cochrane Database Syst Rev, 2005, 3, CD001122.
20. Franks S: Assessment and management of anovulatory infertility in polycystic ovary syndrome. Endocrinol Metab Clin North Am, 2003, 32, 639-651.
21. Froment P, Gizard F, Defever D, Staels B, Dupont J, Monget P: Peroxisome proliferator-activated receptors in reproductive tissues: from gametogenesis to parturition. J Endocrinol, 2006, 189, 199-209.
22. Ghazeeri G, Kutteh WH, Bryer-Ash M, Haas D, Ke RW: Effect of rosiglitasone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome. Fertil Steril, 2003, 79, 562-566.
23. Glueck CJ, Streicher P, Wang P: Treatment of polycystic ovary syndrome with insulin-lowering agents. Expert Opin Pharmacother, 2002, 3, 1177-1189.
24. Glueck CJ, Goldenberg N, Streicher P, Wang P: Metformin and gestational diabetes. Curr Diab Rep, 2003, 3, 303-312.
25. Goodarzi MO, Korenman SG: The importance of insulin resistance in polycystic ovary syndrome. Fertil Steril, 2003, 80, 255-258.
26. Guzick DS: Polycystic ovary syndrome. Obstet Gynecol, 2004, 103, 181-193.
27. Homburg R: Clomiphene citrate - end of an era?, Hum Reprod, 2005, 20, 2043-2051.
28. Homko CJ, Sivan E, Reece AE: Is there a role for oral antihyperglycemics in gestational diabetes and type 2 diabetes mellitus?. Treat Endocrinol, 2004, 3, 133-139.
29. Hoyt KL, Schmidt MC: Polycystic ovary (Stein-Leventhal) syndrome: etiology, complications, and treatment. Clin Lab Sci, 2004, 17, 155-163.
30. Kahn JA, Gordon CM: Polycystic ovary syndrome. Adolesc Med, 1999, 10, 321-336.
31. Kidson W: Polycystic ovary syndrome: a new direction in treatment. Med J Aust, 1998, 169, 537-540.
32. Lam PM, Cheung LP, Haines C: Revisit of metformin treatment in polycystic ovarian syndrome. Gynecol Endocrinol, 2004, 19, 33-39.
33. Leclair C, Patton PE: Advances in polycystic ovary syndrome treatment: metformin and ovarian diathermy. Curr Womens Health Rep, 2002, 2, 333-337.
34. Legro RS, Castracane VD, Kauffman RP: Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstet Gynecol Surv, 2004, 59, 141-154.
35. Lord JM, Flight IH, Norman RJ: Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev, 2003, 3, CD003053.
36. Moran LJ, Brinkworth G, Noakes M, Norman RJ: Effects of lifestyle modification in polycystic ovarian syndrome. Reprod Biomed Online, 2006, 12, 569-578.
37. Pelusi C, Pasquali R: Polycystic ovary syndrome in adolescents. Pathophysiology and treatment implications. Treat Endocrinol, 2003, 2, 215-230.
38. Pfeifer SM, Dayal M: Treatment of the adolescent patient with polycystic ovary syndrome. Obstet Gynecol Clin North Am, 2003, 30, 337-352.
39. Plosker SM: Polycystic ovarian syndrome and insulin resistance. Med Health RI, 2003, 86, 12-15.
40. Poretsky L, Cataldo NA, Rosenwaks Z, Giudice LC: The insulin-related ovarian regulatory system in health and disease. Endocr Rev, 1999, 20, 535-582.
41. Pritts EA: Treatment of the infertile patient with polycystic ovarian syndrome. Obstet Gynecol Surv, 2002, 57, 587-597.
42. Pugeat M, Ducluzeau PH: Insulin resistance, polycystic ovary syndrome and metformin. Drugs, 1999, 58, Suppl 1, 41-46.
43. Saleh AM, Khalil HS: Review of nonsurgical and surgical treatment and the role of insulin-sensitizing agents in the management of infertile women with polycystic ovary syndrome. Acta Obstet Gynecol Scand, 2004, 83, 614-621.
44. Seli E, Duleba AJ: Treatment of PCOS with metformin and other insulin-sensitizing agents. Curr Diab Rep, 2004, 4, 69-75.
45. Simmons D, Walters BN, Rowan JA, McIntyre HD: Metformin therapy and diabetes in pregnancy. Med J Aust, 2004, 180, 462-464.
46. Sozen I, Arici A: Hyperinsulinism and its interaction with hyperandrogenism in polycystic ovary syndrome. Obstet Gynecol Surv, 2000, 55, 321-328.
47. Teede HJ, Meyer C, Norman RJ: Insulin-sensitisers in the treatment of polycystic ovary syndrome. Expert Opin Pharmacother, 2005, 6, 2419-2427.
48. Wiegratz I, Kuhl H: Long-cycle treatment with oral contraceptives. Drugs, 2004, 64, 2447-2462.